Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...

In a report released today, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target ...

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker Corporation announced the launch of the LUMOS™ II ILIM , a quantum cascade laser (QCL) based infrared imaging ...

Merit Financial Group LLC acquired a new stake in shares of Bruker Co. (NASDAQ:BRKR – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 5,115 shares of the medical ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share.

In a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data, technical ...

Bruker shares fell by 2.5%, Illumina by 3.3%, Quanterix by 2.8%, Bio-Techne by 5%, 10X Genomics by 8.8%, and Qiagen by 3.5%. Analysts have noted that this move by the NIH could have a material impact ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...